Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + docetaxel + filgrastim
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous (for Filgrastim)
01
Overview
A combination chemotherapy regimen consisting of **gemcitabine** (a nucleoside analog antimetabolite that inhibits DNA synthesis), **docetaxel** (a taxane that stabilizes microtubules and inhibits cell division), and **filgrastim** (a recombinant granulocyte colony-stimulating factor that stimulates neutrophil proliferation). This combination is investigated primarily in metastatic or advanced solid tumors, including refractory sarcomas and breast cancer, with filgrastim used to support higher dose intensity by reducing neutropenia risk. The combination is supported by the non-overlapping mechanisms and toxicity profiles of gemcitabine and docetaxel and the hematopoietic support from filgrastim[1][2][3].
- Brand names
- GemzarTaxotereNeupogen
- Other names
- Gemcitabine hydrochlorideDocetaxel anhydrousFilgrastim-sndzG-CSF
02
Targets
DNA polymerase familyTUBB (Tubulin (alpha and beta subunits))CSF3R (Granulocyte colony-stimulating factor receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + docetaxel + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + docetaxel + filgrastim.